Cargando…
A new therapy for transthyretin amyloidosis, no longer an orphan condition
Amyloid cardiomyopathy is a condition characterized by intra-myocardial deposit of protein-like material, in fibrillar shape (amyloid), which presence determine a progressive thickening and stiffening of the cardiac walls leading to a cardiac dysfunction. The proteins most often involved with cardia...
Autores principales: | Quarta, Candida Cristina, Tinuper, Anna Laura, Milandri, Agnese, Gagliardi, Christian, Caponeti, Giuseppe, Rapezzi, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270922/ https://www.ncbi.nlm.nih.gov/pubmed/32523456 http://dx.doi.org/10.1093/eurheartj/suaa077 |
Ejemplares similares
-
Corrigendum to: A new therapy for Transthyretin amyloidosis, no longer an orphan condition
Publicado: (2021) -
Glu89Gln transthyretin-related amyloidosis in Italy and Bulgaria: does geographic area influence phenotype beyond the shared mutation?
por: Gagliardi, Christian, et al.
Publicado: (2015) -
Coexistence of degenerative aortic stenosis and wild type transthyretin-related cardiac amyloidosis: a potentially dangerous association that can be non-invasively identified
por: Longhi, Simone, et al.
Publicado: (2015) -
Prevalence, risk factors and correlation with cardiac involvement of carpal tunnel syndrome in amyloidosis
por: Milandri, Agnese, et al.
Publicado: (2015) -
Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017)